NVTA · Invitae Corp - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Annual Quarterly

Income Statement

Line item	FY 2022	FY 2021	FY 2020	FY 2019	FY 43465	FY 2017
Revenue	$516.30M	$460.45M	$279.60M	$216.82M	$25.05M	$68.22M
Cost of Revenue	$417.26M	$348.67M	$198.28M	$118.10M	$80.11M	-
Gross Profit	$99.05M	$111.78M	$81.32M	$98.72M	($55.06M)	-
R&D	$402.09M	$416.09M	$240.60M	$141.53M	$63.50M	$46.47M
SG&A	$192.31M	$248.07M	$324.57M	$79.07M	$52.23M	$39.47M
Total Operating Expenses	$3.63B	$931.77M	-	-	$270.26M	$189.50M
D&A	$142.07M	$80.47M	$39.05M	$16.21M	$13.54M	$9.18M
Operating Income	($3.12B)	($391.64M)	($652.17M)	($244.11M)	($122.56M)	($121.28M)
Interest Expense	$56.75M	$49.90M	$29.77M	$12.41M	$7.03M	$3.65M
Income Tax	($44.90M)	($36.86M)	($112.10M)	($18.45M)	($2.80M)	($1.86M)
Net Income	($3.11B)	($379.01M)	($602.17M)	($241.97M)	($129.35M)	($123.38M)
EPS - Basic	($13.18)	($4.47)	-	-	-	-
EPS - Diluted	($13.18)	($4.47)	-	-	-	-

Balance Sheet

Line item	FY 2022	FY 2021	FY 2020	FY 2019	FY 43465	FY 2017
Cash & Equivalents	$257.49M	$923.25M	$124.79M	$151.39M	$112.16M	$12.05M
Accounts Receivable	$96.15M	$66.23M	$47.72M	$32.54M	$26.30M	$10.42M
Inventory	$30.39M	$33.52M	$32.03M	$6.60M	$8.30M	-
Accounts Payable	$13.98M	$21.13M	$25.20M	$10.32M	$7.81M	$8.61M
Current Assets	$693.13M	$1.18B	$453.93M	$442.40M	$165.44M	$86.68M
Total Assets	$1.95B	$4.92B	$3.43B	$781.60M	$282.96M	$211.08M
Current Liabilities	$108.09M	$144.09M	$121.75M	$81.86M	$36.31M	$33.39M
Long-term Debt	-	-	-	$0	$74.48M	$39.08M
Total Liabilities	$1.85B	$1.94B	$1.45B	$401.96M	$121.12M	$89.28M
Stockholders' Equity	$101.84M	$2.98B	$1.98B	$379.64M	$161.84M	$121.79M
Retained Earnings	($4.83B)	($1.72B)	($1.36B)	($758.68M)	($516.71M)	($398.60M)

Cash Flow

Line item	FY 2022	FY 2021	FY 2020	FY 2019	FY 43465	FY 2017
Operating Cash Flow	($492.96M)	($559.82M)	($298.50M)	($145.05M)	($76.32M)	($97.98M)
Investing Cash Flow	($174.80M)	($204.08M)	($400.58M)	($280.31M)	$16.06M	($36.95M)
Financing Cash Flow	$1.76M	$1.57B	$672.99M	$464.77M	$53.71M	$80.87M
CapEx	$53.31M	$54.72M	$22.86M	$20.05M	$5.97M	$6.67M
Free Cash Flow	($546.27M)	($614.53M)	($321.37M)	($165.10M)	($82.29M)	($104.66M)

Ratios

Metric	FY 2022	FY 2021	FY 2020	FY 2019	FY 43465	FY 2017
Profitability
Gross margin	19.2%	24.3%	29.1%	45.5%	-219.8%	-
Operating margin	-604.0%	-85.1%	-233.3%	-112.6%	-489.3%	-177.8%
EBITDA margin	-576.5%	-67.6%	-219.3%	-105.1%	-435.2%	-164.3%
Net margin	-601.6%	-82.3%	-215.4%	-111.6%	-516.4%	-180.9%
Free cash flow margin	-105.8%	-133.5%	-114.9%	-76.1%	-328.5%	-153.4%
FCF / Net income	0.18	1.62	0.53	0.68	0.64	0.85
R&D / Revenue	77.9%	90.4%	86.1%	65.3%	253.5%	68.1%
SG&A / Revenue	37.2%	53.9%	116.1%	36.5%	208.5%	57.9%
Effective tax rate	-	-	-	-	-	-
Return on assets	-159.0%	-7.7%	-17.6%	-31.0%	-45.7%	-58.5%
Return on equity	-3050.3%	-12.7%	-30.5%	-63.7%	-79.9%	-101.3%
Return on invested capital	-	-	-	-50.8%	-41.0%	-59.6%
Liquidity
Current ratio	6.41	8.18	3.73	5.40	4.56	2.60
Quick ratio	6.13	7.95	3.47	5.32	4.33	2.60
Cash ratio	2.38	6.41	1.03	1.85	3.09	0.36
Leverage
Debt / Equity	-	-	-	0.00	0.46	0.32
Debt / Assets	-	-	-	0.00	0.26	0.19
Debt / EBITDA	-	-	-	-	-	-
Interest coverage	-55.0x	-7.8x	-21.9x	-19.7x	-17.4x	-33.2x
Equity multiplier	19.19	1.65	1.74	2.06	1.75	1.73
Liabilities / Assets	0.95	0.39	0.42	0.51	0.43	0.42
Efficiency
Asset turnover	0.26	0.09	0.08	0.28	0.09	0.32
Inventory turnover	13.73	10.40	6.19	17.89	9.65	-
Days sales outstanding	68d	52d	62d	55d	383d	56d
Days inventory outstanding	27d	35d	59d	20d	38d	-
Days payable outstanding	12d	22d	46d	32d	36d	-
Cash conversion cycle	82d	65d	75d	43d	385d	-
Valuation
P / E	-	-	-	-	-	-
P / B	-	-	-	-	-	-
P / S	-	-	-	-	-	-
EV / EBITDA	-	-	-	-	-	-
Growth
Revenue growth (YoY)	12.1%	64.7%	29.0%	-	-	172.4%
Revenue CAGR (3y)	33.5%	-	60.0%	105.3%	-	-
Revenue CAGR (5y)	49.9%	79.0%	352.1%	-	-	-
Gross profit growth (YoY)	-11.4%	37.5%	-17.6%	-	-	-
Operating income growth (YoY)	-696.2%	39.9%	-167.2%	-	-	-21.1%
Net income growth (YoY)	-719.6%	37.1%	-148.9%	-	-	-23.1%
EPS growth (YoY)	-194.9%	-	-	-	-	-
EPS CAGR (3y)	-	-	-	-	-	-
EPS CAGR (5y)	-	-	-	-	-	-
FCF growth (YoY)	11.1%	-91.2%	-94.6%	-	-	-19.0%
FCF CAGR (5y)	-	-	-	-	-	-
Book value growth (YoY)	-96.6%	50.7%	420.6%	-	-	22.9%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2021-12-31.

Product / service

$738.64M total

Diagnostic Tests$444.07M · 60.1%

Test Revenue Centralized$276.92M · 37.5%

Collaboration And Genome Network$16.38M · 2.2%

Test Revenue Decentralized$1.28M · 0.2%

Geographic

$460.45M total

US$404.01M · 87.7%

Rest Of World$48.88M · 10.6%

CA$7.55M · 1.6%

Stability scores

Altman Z′

FY 2022 · bankruptcy risk

-6.55

Distress

Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.

Piotroski F-score

FY 2022 · 9-point quality

2/9

Weak

✗Net income positive
✗Operating cash flow positive
✗ROA improved YoY
✓Cash flow > net income
-Long-term debt decreased
✗Current ratio improved
✗No share dilution
✗Gross margin improved
✓Asset turnover improved

Peer comparison

Same SIC group: Services-Medical Laboratories

Company	Revenue (last FY)	Net margin	ROE
NTRA	$2.31B	-9.0%	-12.2%
GH	$982.02M	-42.4%	419.2%
LH	$13.95B	6.3%	10.2%
DGX	$11.04B	9.0%	13.8%
CSTL	$344.23M	-7.0%	-5.1%

Comparing Invitae Corp against the 5 most active filers in the same SIC group.